Title:
STAR Infigratinib vs Gem/Cis Cholangio View
Description: A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)
Indication:
Biliary Cancer
Location:
Texas Oncology-McAllen
Phase: III
Title:
STAR Infigratinib vs Gem/Cis Cholangio View
Description: A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)
Indication:
Biliary Cancer
Location:
Texas Oncology-Weslaco
Phase: III
Title:
Ph 3 Tuca/Placbo + T-DM1 HER2+ View
Description: STAR: Randomized, double-blind, phase 3 study of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer (HER2CLIMB-02)(SGNTUC-016)
Indication:
Breast Cancer
Location:
Texas Oncology-McAllen
Phase: III
Title:
Ph 3 Tuca/Placbo + T-DM1 HER2+ View
Description: STAR: Randomized, double-blind, phase 3 study of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer (HER2CLIMB-02)(SGNTUC-016)
Indication:
Breast Cancer
Location:
Texas Oncology-Weslaco
Phase: III
Title:
STAR PH3 Pacritinib vs MD choice in MF View
Description: A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician''s Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia (Platelets Counts <50,000/µL) (PAC203)
Indication:
Essential Thrombocythemia
Location:
Texas Oncology-Harlingen
Phase: III
Title:
STAR PH3 Pacritinib vs MD choice in MF View
Description: A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician''s Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia (Platelets Counts <50,000/µL) (PAC203)
Indication:
Essential Thrombocythemia
Location:
Texas Oncology-McAllen
Phase: III
Title:
STAR PH3 Pacritinib vs MD choice in MF View
Description: A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician''s Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia (Platelets Counts <50,000/µL) (PAC203)
Indication:
Essential Thrombocythemia
Location:
Texas Oncology-Weslaco
Phase: III
Title:
STAR Infigratinib vs Gem/Cis Cholangio View
Description: A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)
Indication:
Gall Bladder Cancer
Location:
Texas Oncology-McAllen
Phase: III
Title:
STAR Infigratinib vs Gem/Cis Cholangio View
Description: A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)
Indication:
Gall Bladder Cancer
Location:
Texas Oncology-Weslaco
Phase: III
Title:
Ph3 GC4419 Oral Mucositis H&N View
Description: ROMAN: Reduction in Oral Mucositis with Avasopasem Manganese (GC4419)- Phase 3 Trial in Patients Receiving Chemoradiotherapy for Locally-Advanced, Non-Metastatic Head and Neck Cancer (GTI-4419-301)
Indication:
Head and Neck Cancer
Location:
Texas Oncology-Harlingen
Phase: III
Title:
Ph3 GC4419 Oral Mucositis H&N View
Description: ROMAN: Reduction in Oral Mucositis with Avasopasem Manganese (GC4419)- Phase 3 Trial in Patients Receiving Chemoradiotherapy for Locally-Advanced, Non-Metastatic Head and Neck Cancer (GTI-4419-301)
Indication:
Head and Neck Cancer
Location:
Texas Oncology-McAllen
Phase: III
Title:
Ph3 GC4419 Oral Mucositis H&N View
Description: ROMAN: Reduction in Oral Mucositis with Avasopasem Manganese (GC4419)- Phase 3 Trial in Patients Receiving Chemoradiotherapy for Locally-Advanced, Non-Metastatic Head and Neck Cancer (GTI-4419-301)
Indication:
Head and Neck Cancer
Location:
Texas Oncology-Weslaco
Phase: III
Title:
STAR Ph3 ALK+ mNSCLC (Brigatinib-3001) View
Description: Brigatinib-3001- A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG®)Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)
Indication:
Lung Cancer
Location:
Texas Oncology-McAllen
Phase: III
Title:
STAR Ph3 ALK+ mNSCLC (Brigatinib-3001) View
Description: Brigatinib-3001- A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG®)Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)
Indication:
Lung Cancer
Location:
Texas Oncology-Weslaco
Phase: III
Title:
STAR Ph3 Peme+PltChem+/-Pemb NSCLC TKI View
Description: A Randomized, Double-Blind, Phase 3 Study of Pemetrexed + PlatinumChemotherapy with or without Pembrolizumab (MK-3475) in TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Participants (KEYNOTE-789; MK-3475-789)
Indication:
Lung Cancer
Location:
Texas Oncology-McAllen
Phase: III
Title:
STAR Ph3 Peme+PltChem+/-Pemb NSCLC TKI View
Description: A Randomized, Double-Blind, Phase 3 Study of Pemetrexed + PlatinumChemotherapy with or without Pembrolizumab (MK-3475) in TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Participants (KEYNOTE-789; MK-3475-789)
Indication:
Lung Cancer
Location:
Texas Oncology-Weslaco
Phase: III
Title:
STAR-PH3 pral(Blu-667) RET-fusion mNSCLC View
Description: A Randomized, Open-Label, Phase 3 Study of Pralsetinib versus Standard of Care for First Line Treatment of RET fusion-positive, Metastatic Non-Small Cell Lung Cancer (BLU-667-2303)
Indication:
Lung Cancer
Location:
Texas Oncology-Harlingen
Phase: III
Title:
STAR-PH3 pral(Blu-667) RET-fusion mNSCLC View
Description: A Randomized, Open-Label, Phase 3 Study of Pralsetinib versus Standard of Care for First Line Treatment of RET fusion-positive, Metastatic Non-Small Cell Lung Cancer (BLU-667-2303)
Indication:
Lung Cancer
Location:
Texas Oncology-McAllen
Phase: III
Title:
STAR-PH3 pral(Blu-667) RET-fusion mNSCLC View
Description: A Randomized, Open-Label, Phase 3 Study of Pralsetinib versus Standard of Care for First Line Treatment of RET fusion-positive, Metastatic Non-Small Cell Lung Cancer (BLU-667-2303)
Indication:
Lung Cancer
Location:
Texas Oncology-Weslaco
Phase: III
Title:
STAR PH3 Pacritinib vs MD choice in MF View
Description: A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician''s Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia (Platelets Counts <50,000/µL) (PAC203)
Indication:
Myelofibrosis
Location:
Texas Oncology-Harlingen
Phase: III
Title:
STAR PH3 Pacritinib vs MD choice in MF View
Description: A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician''s Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia (Platelets Counts <50,000/µL) (PAC203)
Indication:
Myelofibrosis
Location:
Texas Oncology-McAllen
Phase: III
Title:
STAR PH3 Pacritinib vs MD choice in MF View
Description: A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician''s Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia (Platelets Counts <50,000/µL) (PAC203)
Indication:
Myelofibrosis
Location:
Texas Oncology-Weslaco
Phase: III
Title:
TTFlds cncmnt w/ PTX recurrent ovn cnr View
Description: ENGOT-ov50 / INNOVATE-3: Pivotal, Randomized, Open-Label Study ofTumor Treating Fields (TTFields, 200kHz) Concomitant with WeeklyPaclitaxel for the Treatment of Recurrent Ovarian Cancer
Indication:
Ovarian Cancer
Location:
Texas Oncology-Harlingen
Phase: III
Title:
TTFlds cncmnt w/ PTX recurrent ovn cnr View
Description: ENGOT-ov50 / INNOVATE-3: Pivotal, Randomized, Open-Label Study ofTumor Treating Fields (TTFields, 200kHz) Concomitant with WeeklyPaclitaxel for the Treatment of Recurrent Ovarian Cancer
Indication:
Ovarian Cancer
Location:
Texas Oncology-McAllen
Phase: III
Title:
TTFlds cncmnt w/ PTX recurrent ovn cnr View
Description: ENGOT-ov50 / INNOVATE-3: Pivotal, Randomized, Open-Label Study ofTumor Treating Fields (TTFields, 200kHz) Concomitant with WeeklyPaclitaxel for the Treatment of Recurrent Ovarian Cancer
Indication:
Ovarian Cancer
Location:
Texas Oncology-Weslaco
Phase: III
Title:
STAR Rucaparib v PhysC mCRPC (TRITON3) View
Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)
Indication:
Prostate Cancer
Location:
Texas Oncology-Harlingen
Phase: III
Title:
STAR Rucaparib v PhysC mCRPC (TRITON3) View
Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)
Indication:
Prostate Cancer
Location:
Texas Oncology-McAllen
Phase: III
Title:
STAR Rucaparib v PhysC mCRPC (TRITON3) View
Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)
Indication:
Prostate Cancer
Location:
Texas Oncology-Weslaco
Phase: III
Title:
STAR Ph3 Nirap+Abirat+Pred mCRPC View
Description: A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Subjects with Metastatic Prostate Cancer(64091742PCR3001)
Indication:
Prostate Cancer
Location:
Texas Oncology-Harlingen
Phase: III
Title:
STAR Ph3 Nirap+Abirat+Pred mCRPC View
Description: A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Subjects with Metastatic Prostate Cancer(64091742PCR3001)
Indication:
Prostate Cancer
Location:
Texas Oncology-McAllen
Phase: III
Title:
STAR Ph3 Nirap+Abirat+Pred mCRPC View
Description: A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Subjects with Metastatic Prostate Cancer(64091742PCR3001)
Indication:
Prostate Cancer
Location:
Texas Oncology-Weslaco
Phase: III
Title:
STAR Ph3 FGFR erdafitinib urothelial View
Description: (42756493BLC3001) A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations (THOR)
Indication:
Urothelial Cancer
Location:
Texas Oncology-McAllen
Phase: III
Title:
STAR Ph3 FGFR erdafitinib urothelial View
Description: (42756493BLC3001) A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations (THOR)
Indication:
Urothelial Cancer
Location:
Texas Oncology-Weslaco
Phase: III
Title:
STAR Ph 3 Infigratinib UC w/ FGFR3 Alt View
Description: QBGJ398-302: Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of Infigratinib for the Adjuvant Treatment of Subjects with Invasive Urothelial Carcinoma with Susceptible FGFR3 Genetic Alterations (PROOF302)
Indication:
Urothelial Cancer
Location:
Texas Oncology-Harlingen
Phase: III
Title:
STAR Ph 3 Infigratinib UC w/ FGFR3 Alt View
Description: QBGJ398-302: Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of Infigratinib for the Adjuvant Treatment of Subjects with Invasive Urothelial Carcinoma with Susceptible FGFR3 Genetic Alterations (PROOF302)
Indication:
Urothelial Cancer
Location:
Texas Oncology-McAllen
Phase: III
Title:
STAR Ph 3 Infigratinib UC w/ FGFR3 Alt View
Description: QBGJ398-302: Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of Infigratinib for the Adjuvant Treatment of Subjects with Invasive Urothelial Carcinoma with Susceptible FGFR3 Genetic Alterations (PROOF302)
Indication:
Urothelial Cancer
Location:
Texas Oncology-Weslaco
Phase: III
Title:
A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma View
Indication:
Lymphomas
Location:
Texas Oncology-McAllen
Phase: III
Title:
A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma View
Indication:
Lymphomas
Location:
Texas Oncology-Weslaco
Phase: III